| |
|
|
|
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
 |
| |
|
| 제 목 |
fWwKkuWpuNS |
|
| 이 름 |
Shannon |
날 짜 |
2018/06/29 |
조 회 |
1 |
|
We've got a joint account trenbolone enanthate steroids Drugmaker Retrophin Inc said it offered to buy therest of Transcept Pharmaceuticals shares it does not already ownfor $4 per share, valuing Transcept at about $75 million.Retrophin's offer represents an 11 percent premium toTranscept's closing share price of $3.59 on the Nasdaq onWednesday.
|
|
|
 |
|
| |
|
|
|
| |
|
|
|
|
|
| |
|
|
|
